| CAS NO: | 1195765-45-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 519.56 |
|---|---|
| Formula | C23H20F3N5O2S2 |
| CAS No. | 1195765-45-7(free base); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 30 mg/mL (57.74 mM) |
| Water: <1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | 30% PEG400+0.5% Tween80+5% Propylene glycol: 8 mg/mL |
| Synonyms | GSK2118436A; GSK-2118436B; GSK 2118436A; GSK2118436B (Dabrafenib Mesylate ); GSK-2118436A; GSK 2118436B. Trade name: Tafinlar. |
| General | Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. |
|---|---|
| Animal model | A375P cells were implanted subcutaneously in female CD1 nu/nu mice and grown to form tumors [1]; Dabrafenib (orally gavage) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice [2]. |
| Formulation | Dissolved in 0.5% hydroxypropylmethylcellulose, 0.2% Tween 80 in pH 8.0 distilled water |
| Dosages | 10, 30, and 100 mg/kg |
| Administration | Administered orally once daily |
| Reference | [1] PLoS One. 2013; 8(7): e67583; [2] Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88. |
Dabrafenib inhibits MAPK signalling in BRAFV600E cells and is abrogated by ARAF or CRAF depletion. PLoS One. 2013; 8(7): e67583. |
Modulation of pharmacodynamic markers by dabrafenib in BRAFV600E tumors. |
Inhibition of BRAFV600E tumor xenograft growth by dabrafenib. |
m.cnreagent.com
